Table 1.
Associations of clinical characteristics with pCR in univariate analysis.
Non-pCR (n = 185) | pCR (n = 49) | P value | |||
---|---|---|---|---|---|
n | % | n | % | ||
Age (year) | 0.182 | ||||
≤35 | 24 | 13.0 | 3 | 6.1 | |
>35 | 161 | 87.0 | 46 | 93.9 | |
Menopausal status | 0.527 | ||||
Premenopausal | 100 | 54.1 | 24 | 49.0 | |
Postmenopausal | 85 | 45.9 | 25 | 51.0 | |
cT stage | 0.389 | ||||
cT1–2 | 124 | 67.0 | 36 | 73.5 | |
cT3–4 | 61 | 33.0 | 13 | 26.5 | |
cN stage | 0.07 | ||||
cN0 | 94 | 50.8 | 32 | 65.3 | |
cN1–3 | 91 | 49.2 | 17 | 34.7 | |
Grade | 0.729 | ||||
G1–2 | 41 | 22.2 | 12 | 24.5 | |
G3 | 144 | 77.8 | 37 | 75.5 | |
ER | 0.472 | ||||
Positive | 105 | 56.8 | 25 | 51.0 | |
Negative | 80 | 43.2 | 24 | 49.0 | |
PR | 0.949 | ||||
Positive | 84 | 45.4 | 22 | 44.9 | |
Negative | 101 | 54.6 | 27 | 55.1 | |
HR | 0.854 | ||||
Positive | 82 | 44.3 | 21 | 42.9 | |
Negative | 103 | 55.7 | 28 | 57.1 | |
Ki-67 | 0.791 | ||||
>30% | 87 | 47.0 | 22 | 44.9 | |
≤30% | 98 | 53.0 | 27 | 55.1 | |
Molecular subtype | 0.607 | ||||
Luminal B/HER2+ | 102 | 55.1 | 25 | 51.0 | |
Nonluminal/HER2+ | 83 | 44.9 | 24 | 49.0 | |
Trastuzumab | 0.004 | ||||
Yes | 64 | 34.6 | 28 | 57.1 | |
No | 121 | 65.4 | 21 | 42.9 |